U.S. Pharma Stock News

If you are wondering whether Winnebago Industries at around US$33.45 is a bargain or a value trap, you are not alone. This article focuses squarely on what the current price might be telling you. The stock has been under pressure recently, with a 12.1% decline over the last week and a 29.1% decline over the past month, while the 1 year return sits at 0.7% and the 5 year return at a 55.4% decline. Recent attention around Winnebago has focused on how demand for recreational vehicles fits into...

If you are wondering whether Penumbra's current share price lines up with its underlying worth, you are not alone. This article is aimed squarely at that question. The stock last closed at US$334.99, with returns of 8.3% year to date and 28.5% over the past year, although the past week and month showed 1.7% and 1.2% declines respectively. Recent coverage around Penumbra has focused on its position in the medical devices space and how investors see its long term growth story. This helps frame...

In recent months, Expand Energy has attracted fresh institutional money, insider share purchases from interim CEO Michael Wichterich, strong Q4 2025 results, and new technology partnerships with Leucipa, Baker Hughes, and Snowflake to improve efficiency and cut emissions. This combination of institutional support, insider conviction, and tech-enabled operational upgrades suggests investors are reassessing how the company is positioned within the U.S. natural gas landscape. Next, we’ll...

Event context and recent price performance SoundHound AI (SOUN) has drawn fresh attention after recent trading, with the share price closing at US$7.47 and posting negative returns over the past week, month, and past 3 months. See our latest analysis for SoundHound AI. While the recent 1 day, 7 day, 30 day, and 90 day share price returns have all been negative and suggest fading momentum around the current US$7.47 level, the 3 year total shareholder return of over 3x shows how volatile the...

If you are wondering whether MDU Resources Group at around US$20.90 is offering good value right now, you are not alone. This article will walk through what the current price might be implying. The stock has seen mixed recent moves, with a 1.7% decline over the last 7 days, a 2.9% gain over 30 days, a 5.2% gain year to date, and a 30.9% return over the past year, while the 3 year and 5 year returns are both a little over double the starting point. Recent headlines around MDU Resources Group...

Earnings beat and higher guidance put Hewlett Packard Enterprise (HPE) in focus Hewlett Packard Enterprise (HPE) has drawn fresh attention after reporting quarterly revenue and earnings per share above expectations, backed by strong networking performance and AI related demand, and by lifting full year profit guidance. See our latest analysis for Hewlett Packard Enterprise. At a share price of $21.58, Hewlett Packard Enterprise has a 1 year total shareholder return of 50.04% and a 3 year...

Ferguson Enterprises (FERG) opened down 3.05% on March 9 after releasing strong results and positive 2026 guidance, as investors focused on weaker U.S. residential trends and a 1% decline in HVAC revenues. See our latest analysis for Ferguson Enterprises. That 5.14% one day share price decline, together with a 16.73% 30 day share price return, points to fading short term momentum. However, the 44.60% one year total shareholder return remains strong. If Ferguson’s latest move has you...

BioMarin Pharmaceutical (NasdaqGS:BMRN) reported new multi year data on VOXZOGO in young children with achondroplasia. The results, from clinical and real world studies, indicate durable gains in skeletal growth and body proportionality when treatment begins before age 2. The data set is being presented at a major clinical genetics conference, highlighting its relevance for both clinicians and patient communities. BioMarin focuses on therapies for rare genetic conditions, and VOXZOGO is a...

Cisco Systems recently presented across several high-profile events, including Mobile World Congress 2026 and Morgan Stanley’s TMT Conference, where management highlighted strong fiscal Q2 2026 demand in AI infrastructure, networking, and security alongside double-digit order growth across regions. However, investors have grown concerned that below-expectation gross margins, memory cost inflation, and cautious forward guidance may limit the benefit of this AI and networking momentum for...

Vertex Pharmaceuticals recently reported that its engineered fusion protein povetacicept met the primary and key secondary endpoints in a Phase 3 RAINIER interim analysis for IgA nephropathy, showing large reductions in urine protein and disease‑related antibodies with a generally manageable safety profile. The company is moving quickly to complete a rolling Biologics License Application for potential accelerated FDA approval, positioning povetacicept as a possible fourth major franchise...

ZTO Express (Cayman) (ZTO) has cancelled 7.37 million Class A shares, trimming its issued share count by about 0.93%, a relatively small move that still slightly increases remaining investors’ proportional ownership. See our latest analysis for ZTO Express (Cayman). At a share price of $23.49, ZTO Express (Cayman) has a 7-day share price return of 4.82% and a 90-day share price return of 9.56%. Its 1-year total shareholder return of 25.23% contrasts with weaker 3 and 5-year total shareholder...

If you are wondering whether Pfizer's current share price reflects fair value or an opportunity, you are not alone. This article focuses squarely on that question. Pfizer's share price recently closed at US$26.86, with returns of 0.9% over the past 7 days, a 2.7% decline over 30 days, a 6.7% gain year to date, and a 12.5% return over 1 year, set against a 20.3% decline over 3 years and a 3.6% decline over 5 years. These mixed returns come as Pfizer moves further away from its pandemic period...

On March 12, 2026, Cellhub announced a partnership with Extreme Networks to deliver integrated wired, wireless, and cellular networking infrastructure for highly regulated healthcare settings through the Hospitals Without Walls program, showcased at the HIMSS 2026 conference in Las Vegas. The alliance highlights how combining Extreme’s AI-powered networking with T-Mobile–backed cellular services could help hospitals extend secure, HIPAA-compliant connectivity beyond traditional campuses into...

In its most recent quarterly update, JFrog reported annual recurring revenue of US$580.4 million, solid customer acquisition efficiency with a roughly 30‑month payback period, and a strong average free cash flow margin over the past year. This combination of recurring revenue growth, disciplined customer acquisition, and substantial free cash generation underscores a business model geared toward self-funded product and platform investment. Next, we will examine how JFrog’s efficient customer...

Procter & Gamble, ticker NYSE:PG, plans to invest nearly $1b in a new Gillette global headquarters and technical innovation center in Boston. The project will consolidate research, engineering, and business operations for Gillette into a single advanced facility. The investment reflects a long term commitment to the Gillette brand and to Boston’s research and manufacturing ecosystem. For investors watching NYSE:PG, this move comes with the stock trading around $150.5 per share. Over the...

EOG Resources (NYSE:EOG) agreed to acquire Encino Acquisition Partners for US$5.6b. The deal expands EOG's operational presence in the Utica Shale basin. The transaction is expected to reshape EOG's production profile and capital allocation priorities over time. EOG Resources is a large independent oil and gas producer with a focus on U.S. shale assets, and the Encino Acquisition Partners deal adds another meaningful position in the Utica Shale. For you as an investor, this kind of...

In recent weeks, Symbotic reported year-over-year revenue growth of 29.4% and swung from a loss to earnings per share of US$0.39, while a company director sold about US$191,431 of Class A shares on March 9, 2026. The company has also consistently exceeded revenue forecasts and is now among the most searched stocks on Zacks.com, highlighting how operational momentum is feeding growing investor interest. Now we’ll examine how Symbotic’s strong revenue growth and improving earnings profile...

In March 2026, AeroVironment reported a sharp year-on-year revenue increase to US$408.05 million for its fiscal third quarter but booked a US$156.55 million net loss driven largely by a US$151.31 million goodwill impairment in its Space unit, while issuing full-year guidance that now calls for US$1.85 billion to US$1.95 billion in revenue and a net loss of US$201 million to US$218 million. At the same time, the company highlighted a record funded backlog and fresh U.S. Army awards alongside...

Wondering if Zions Bancorporation National Association is offering good value at its current price, or if the easy money has already been made? The stock last closed at US$54.24, with a 7 day return of a 5.6% decline and a 30 day return of a 15.4% decline, set against a 1 year return of 19.3% and a 3 year return of 90.0%. Recent coverage has focused on how regional banks are being reassessed by investors, with Zions often cited in discussions about balance sheet strength and interest rate...

Zimmer Biomet overview and recent returns Zimmer Biomet Holdings (ZBH) has drawn fresh attention after recent share price moves, with the stock showing mixed performance across different timeframes. This may prompt investors to recheck expectations and valuation. Over the past month, Zimmer Biomet’s share price return is about 1%, while the past 3 months show a gain of roughly 1%. Year to date, the stock is up around 3%, but the 1 year total return is a decline of about 13%. See our latest...

If you are wondering whether Coca-Cola is fairly priced or if the recent share price leaves some value on the table, this article will walk you through what the numbers are actually saying about the stock. The share price recently closed at US$77.61, with returns of 0.8% over 7 days, 1.0% over 30 days, 12.3% year to date, 15.6% over 1 year, 40.7% over 3 years and 78.1% over 5 years. These figures give useful context before comparing that price to different valuation estimates. Recent...

Vistra's EVP and General Counsel, Stephanie Zapata Moore, sold 10,000 shares of NYSE:VST under a pre arranged trading plan. The insider sale followed new nuclear power agreements with major technology clients. The transaction also came after an expansion of Vistra's Battery Rewards program in Texas. For investors watching NYSE:VST, this insider move comes after a period of strong share price appreciation over the past year, with the stock up 36% and the current share price at $159.58. Over...

Oracle (ORCL) just posted its Q3 2026 numbers, with revenue of US$17.2b and basic EPS of US$1.29, anchored by trailing 12 month EPS of US$5.69 on revenue of US$64.1b. Over recent periods, the company has seen revenue move from US$14.1b in Q3 2025 to US$17.2b in Q3 2026, while quarterly basic EPS shifted from US$1.05 to US$1.29, setting up a story where expanding trailing net profit margins are front and center for investors assessing the quality of these results. See our full analysis for...

If you are wondering whether RTX is reasonably priced after its recent run, this article will walk through what the current share price might be implying about the company’s value. RTX last closed at US$203.04, with a 7 day return of a 0.4% decline, 30 day return of 4.0%, year to date return of 8.4%, 1 year return of 59.8% and a 3 year return of 121.0%. This naturally raises questions about how much optimism or risk is now baked into the stock. Recent moves in RTX have played out against a...